Screening for dilated cardiomyopathy in immediate family members: to whom, how, when (and where)

Maurizio Pieroni,Michele Ciabattini,Chiara Zocchi

DOI: https://doi.org/10.1093/eurheartjsupp/suae024

2024-04-01

European Heart Journal Supplements

Abstract:Abstract Dilated cardiomyopathy (DCM) is defined by the presence of left ventricular dilation and systolic dysfunction in the absence of coronary artery disease, valvular disease, congenital heart disease, or altered haemodynamic conditions. Dilated cardiomyopathy can recognize multiple aetiologies, including infectious processes, effect of toxic substances, immunological mechanisms, and genetic causes. In recent years, many genes coding for proteins involved in the structure and function of the cardiomyocytes have been associated with the development of DCM, making the identification of familial forms increasingly frequent. At the same time, an ever-increasing use of cardiac magnetic resonance imaging has made it possible to identify early morpho-functional alterations in subjects with initial forms of the disease, or carriers of pathogenic genetic variants. The increasingly in-depth understanding of the genetic and molecular mechanisms operating in DCM has also favoured the development of new therapeutic strategies including drugs with molecular targets and gene therapies. In this panorama, screening of family members of patients affected by DCM represents an important tool for early diagnosis, treatment, and prognostic stratification. In relation to its clinical relevance and its complexity, it is important that family screening and follow-up of identified patients are carried out in units dedicated to the treatment and study of cardiomyopathies.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The paper primarily explores the screening of first-degree relatives of patients with dilated cardiomyopathy (DCM). Specifically, the paper aims to address the following aspects:

1. **Early Diagnosis and Treatment**: Achieving early diagnosis and potential treatment of DCM through screening of first-degree relatives. Since DCM has a genetic predisposition, screening family members helps in the early detection of potential diseases.

2. **Clinical Evaluation Methods**: The paper discusses various clinical evaluation methods, including electrocardiogram (ECG), conventional echocardiography, and cardiac magnetic resonance imaging (CMR). These techniques can help identify early morphological and functional changes.

3. **Importance of Genetic Testing**: With a deeper understanding of the genetic mechanisms of DCM, genetic testing has become an important tool for diagnosis and prognosis. The paper emphasizes the value of genetic analysis in family members of DCM patients and points out that the presence of certain specific gene variants (such as desmosomal genes) may impact clinical management.

4. **Necessity of Multidimensional Assessment**: Relying solely on family history or clinical information is insufficient to comprehensively identify cases among DCM family members. A comprehensive assessment combining clinical, instrumental examinations, and genetic testing is required.

5. **Selection of Screening and Follow-up Locations**: It is recommended to conduct screening and follow-up in specialized cardiomyopathy research and treatment units to ensure professionalism and accuracy.

In summary, the paper aims to improve the screening efficiency of family members of DCM patients through the comprehensive use of various diagnostic techniques and genetic analysis methods, thereby achieving early diagnosis and intervention of the disease.